NIH study finds two doses of HPV vaccine may be as protective as full course – 1
Narrator: This is NIH Health Matters. I’m Joe Balintfy. An NIH study has shown that two doses of a human papillomavirus or HPV vaccine may be as effective as the current standard three-dose regimen.
Kreimer: The vaccine is called Cervarix.
Narrator: Dr. Aimée Kreimer at the NIH is the lead author of the study.
Kreimer: So this vaccine is intended to protect against HPV type 16 and HPV type 18.
Narrator: Cervarix is one of two vaccines approved by the FDA to protect against persistent infection with those two cancer-causing HPV types, which together account for 70 percent of all cervical cancer cases. About 250,000 women die from the disease worldwide. For more on this study, visit www.cancer.gov. Health Matters is produced by the National Institutes of Health, part of the U.S. Department of Health and Human Services.
About NIH Radio
NIH Radio offers free audio news programs from the National Institutes of Health, your reliable source for health information.
All NIH Radio content is in the public domain and can be used without charge or restriction provided that it is not used to misrepresent our agency nor used to suggest we endorse any private organization, product, or service.
NIH Radio is a service of the Office of Communications & Public Liaison.